Research Topics
| Franca CentorrinoSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or bothFranca Centorrino
Schizophrenia and Bipolar Disorder Program, McLean Hospital, Belmont 02478, and Department of Psychiatry, Harvard Medical School, Cambridge, MA, USA
Hum Psychopharmacol 21:189-93. 2006..Bipolar disorder (BPD) is often comorbid with obsessive-compulsive (OCD) and other anxiety disorders, but the impact of such comorbidity on long-term outcome has not been evaluated systematically...
Health and economic burden of metabolic comorbidity among individuals with bipolar disorderFranca Centorrino
Schizophrenia Bipolar Disorder and Psychopharmacology Programs, McLean Division of Massachusetts General Hospital, Belmont, MA 02478, USA
J Clin Psychopharmacol 29:595-600. 2009..To compare the prevalence and health care costs of metabolic conditions in patients with bipolar disorder to age- and sex-matched control patients using a large insurance claims database...- Hospital use of antipsychotic drugs: polytherapyFranca Centorrino
Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA 02115, USA
Compr Psychiatry 49:65-9. 2008..Growing acceptance of new psychotropic drugs encouraged a survey of current use of antipsychotic drugs alone and in combinations, with comparisons with previous findings... - Use of combinations of antipsychotics: McLean Hospital inpatients, 2002Franca Centorrino
Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA 02478-9106, USA
Hum Psychopharmacol 20:485-92. 2005.... - Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patientsFranca Centorrino
Harvard Medical School and McLean Hospital, Belmont, MA 02478-9106, USA
J Psychiatr Pract 11:241-7. 2005..Since aripiprazole is likely to be considered for obese patients, body weight should be considered in establishing adequate doses. Controlled trials of this antipsychotic agent in disorders other than schizophrenia are needed... - Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004Franca Centorrino
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
Hum Psychopharmacol 25:179-86. 2010..We tested the hypothesis that combinations and total daily doses of psychotropics for hospitalized patients diagnosed with major psychiatric disorders are rising... - Ziprasidone: first year experience in a hospital settingFranca Centorrino
Schizophrenia and Bipolar Disorder Clinic, McLean Hospital, Belmont, MA 02478-9106, USA
J Psychiatr Pract 10:361-7. 2004..CONCLUSIONS: Ziprasidone was well tolerated by hospitalized patients with various major psychiatric disorders and may be of value in conditions other than schizophrenia... - Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefitsFranca Centorrino
Department of Psychiatry and Neuroscience Program, Harvard Medical School and Bipolar and Psychotic Disorders Clinic, McLean Hospital, Boston, MA USA
Am J Psychiatry 161:700-6. 2004.... - Oxcarbazepine: clinical experience with hospitalized psychiatric patientsFranca Centorrino
Consolidated Department of Psychiatry, Harvard Medical School, Boston, MA, USA
Bipolar Disord 5:370-4. 2003.... - Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disordersFranca Centorrino
Department of Psychiatry, Harvard Medical School, Boston, USA
Am J Psychiatry 160:1348-50. 2003..The authors compared the new extended-release and standard preparations of divalproex sodium... - Inpatient antipsychotic drug use in 1998, 1993, and 1989Franca Centorrino
Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA 02478 9106, USA
Am J Psychiatry 159:1932-5. 2002..Patterns of clinical use of antipsychotic agents have changed greatly in the past decade. The authors' goal was to examine these patterns... - Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropicsFranca Centorrino
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
Hum Psychopharmacol 27:521-6. 2012..Although the literature on metabolic syndrome in psychiatry has expanded in recent years, we seek to elucidate some of the remaining gaps by examining a severely and chronically ill population heavily treated with pharmacological agents... - An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorderFranca Centorrino
McLean Hospital, Harvard Medical School, Boston, MA, USA
Hum Psychopharmacol 22:455-62. 2007..To determine the effect of intramuscular (IM) olanzapine in severely agitated patients... - Lithium treatment reduces suicide risk in recurrent major depressive disorderFrancesca Guzzetta
Department of Psychiatry, Harvard Medical School, Boston, MA, USA
J Clin Psychiatry 68:380-3. 2007..Since lithium shows major antisuicidal effects in bipolar disorders and in heterogeneous mood disorder samples, we evaluated evidence of antisuicidal effects of lithium in patients with recurrent MDD... - Antipsychotic drug use: McLean Hospital, 2002Franca Centorrino
Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, USA
Hum Psychopharmacol 20:355-8. 2005..Major changes in antipsychotic treatment in recent years encouraged a survey of inpatient practice in 2002, compared with earlier samples... - Weygandt's On the Mixed States of Manic-Depressive Insanity: a translation and commentary on its significance in the evolution of the concept of bipolar disorderPaola Salvatore
Department of Psychiatry and the Neuroscience Program, Harvard Medical School, Boston, Mass, USA
Harv Rev Psychiatry 10:255-75. 2002.... - Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agentsJames P Kelleher
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
CNS Drugs 16:249-61. 2002..These new formulations and agents should broaden options for the treatment of psychosis... 
Comparison of mania patients suitable for treatment trials versus clinical treatmentAlessandra Talamo
Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, Massachusetts, USA
Hum Psychopharmacol 23:447-54. 2008..The pilot study is limited in numbers and exposure times with which to test for the minor differences between "research subjects" and "clinical patients."..- EEG abnormalities during treatment with typical and atypical antipsychoticsFranca Centorrino
Bipolar and Psychotic Disorder Program, McLean Hospital, MA 02478, USA
Am J Psychiatry 159:109-15. 2002..Much less is known about EEG effects of newer antipsychotics. The present study therefore examined the risk of EEG abnormalities associated with various antipsychotic drugs... - Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Arch Gen Psychiatry 60:1079-88. 2003.... - Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trialsMichael C Smith
Rush Epilepsy Center, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
Epilepsy Behav 5:746-51. 2004..Although the results of the current analyses must be considered highly tentative due to the open-label nature of the trials included, the findings do suggest broad clinical superiority of the new ER preparation...